[1] KAROLI NA, REBROV AP. Endothelial dysfunction in patients with chronic obstructive pulmonary disease in combination with coronary heart disease[J]. Ter Arkh, 2019, 91(3): 22.
[2] 岳冬梅, 包敏敏, 周海霞, 等. 老年冠心病人纤维蛋白原水平与冠脉狭窄严重程度的相关性[J]. 心血管康复医学杂志, 2018, 27(2): 27.
[3] 余晗俏, 俞章平, 钟忆周, 等. 老年冠心病患者血清B型利钠肽和高敏C反应蛋白水平与临床预后的关系[J]. 中国心血管杂志, 2017, 22(2): 113. doi: 10.3969/j.issn.1007-5410.2017.02.008
[4] 陈建芸, 李林海, 朱丹萍, 等. 凝血检测项目在冠心病患者中的结果分析[J]. 生物技术通讯, 2017, 28(2): 149. doi: 10.3969/j.issn.1009-0002.2017.02.017
[5] MALIK AH, SJETTY S, KAR K, et al. Effect of β-blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis[J]. J Geriatr Cardiol, 2019, 6(3): 291.
[6] 颜红兵. 临床冠心病诊断与治疗指南[M]. 北京: 人民卫生出版社, 2010.
[7] XU H, CHEN Z, SHANG QH, et al. Asymmetric dimethylarginine predicts one-year recurrent cardiovascular events: potential biomarker of "toxin syndrome" in coronary heart disease[J]. Chin J Integr Med, 2019, 25(5): 327. doi: 10.1007/s11655-019-2701-y
[8] 叶单单, 陈静雯. 高压氧治疗对冠心病患者血浆D-二聚体影响的研究[J]. 中华保健医学杂志, 2018, 20(1): 88.
[9] 王茂军, 程亚玲. 曲美他嗪对老年冠状动脉粥样硬化性心脏病伴慢性心力衰竭患者临床疗效和纤溶因子表达的影响[J]. 中国医药, 2017, 12(11): 1620.
[10] 马涛. 颅脑损伤后凝血功能障碍的机制及干预措施[J]. 中国临床神经外科杂志, 2017, 22(8): 601.
[11] HOLY EW, BESLER C, REINER MF, et al. High-density lipoprotein from patients with coronary heart disease loses anti-thrombotic effects on endothelial cells: impact on arterial thrombus formation[J]. Thromb Haemost, 2014, 112(5): 1024.
[12] LOWE G, RUMLEY A. The relevance of coagulation in cardiovascular disease: what do the biomarkers tell us[J]. Thromb Haemost, 2014, 112(5): 860.
[13] WANNAMETHEE SG, PAPACOSTA O, LAWLOR DA, et al. Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men The British Regional Heart Study and British Women's Heart Health Study[J]. Diabetologia, 2012, 55(1): 80. doi: 10.1007/s00125-011-2284-4
[14] 赵东明, 刘格, 张荣秋, 等. 内皮抑素-血管内皮细胞抑制因子重组腺病毒对同型半胱氨酸致人血管内皮细胞损伤的拮抗作用[J]. 中国动脉硬化杂志, 2018, 26(4): 373. doi: 10.3969/j.issn.1007-3949.2018.04.009
[15] 王菲, 刘婕瑜, 李梦丹, 等. 3种抗氧化剂对亚砷酸钠染毒人膀胱上皮细胞血管内皮生长因子表达的拮抗作用研究[J]. 环境与健康杂志, 2017, 34(4): 283.
[16] IGNATOVA YS, KARETNIKOVA VN, HORLAMPENKO AA, et al. The marker of adverse prognosis 1.5-anhydroglucitol in patients with coronary heart disease in the long-term period after planned myocardial revascularization[J]. Ter Arkh, 2019, 91(4): 48.
[17] LANGARI SH, BAHAR A, ASADIAN L, et al. Coronary heart disease and ABO blood group in diabetic women: a case-control study[J]. Sci Rep, 2019, 9(1): 7441. doi: 10.1038/s41598-019-43890-4
[18] WANG J, JIANG J, ZHANG Y, et al. Retinal and choroidal vascular changes in coronary heart disease: an optical coherence tomography angiography study[J]. Biomed Opt Express, 2019, 10(4): 1532.
[19] 李晨怡, 陈佳, 施向凡. 非酒精性脂肪性肝病与冠心病患病率和严重程度以及预后的相关性[J]. 中国医学科学院学报, 2019, 41(2): 156.
[20] 郭晓倩, 任玮, 李艳. 组织型纤溶酶原激活物-抑制剂复合物与冠心病风险的相关性研究[J]. 中华检验医学杂志, 2018, 41(6): 420. doi: 10.3760/cma.j.issn.1009-9158.2018.06.003